Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $12.00 at Robert W. Baird

Taysha Gene Therapies (NASDAQ:TSHA) had its price objective hoisted by Robert W. Baird from $7.00 to $12.00 in a research report report published on Thursday morning, Marketbeat Ratings reports. They currently have an outperform rating on the stock.

A number of other equities analysts have also recently weighed in on TSHA. Chardan Capital upped their price target on Taysha Gene Therapies from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Tuesday, August 12th. Needham & Company LLC boosted their target price on shares of Taysha Gene Therapies from $8.00 to $10.00 and gave the stock a “buy” rating in a research report on Thursday. Wells Fargo & Company raised their price target on shares of Taysha Gene Therapies from $7.50 to $8.00 and gave the company an “overweight” rating in a report on Wednesday, August 13th. Finally, Bank of America assumed coverage on shares of Taysha Gene Therapies in a research note on Friday, July 11th. They set a “buy” rating and a $8.00 price target on the stock. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $9.00.

Taysha Gene Therapies Stock Down 2.5%

Shares of NASDAQ TSHA opened at $4.76 on Thursday. The stock has a fifty day moving average price of $3.03 and a 200 day moving average price of $2.48. The company has a current ratio of 12.48, a quick ratio of 12.48 and a debt-to-equity ratio of 0.17. Taysha Gene Therapies has a 12-month low of $1.05 and a 12-month high of $5.40. The company has a market cap of $1.30 billion, a P/E ratio of -14.00 and a beta of 0.99.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its earnings results on Tuesday, August 12th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.02). Taysha Gene Therapies had a negative return on equity of 78.44% and a negative net margin of 1,144.97%.The company had revenue of $1.99 million during the quarter, compared to analysts’ expectations of $1.61 million. Research analysts anticipate that Taysha Gene Therapies will post -0.35 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Sukumar Nagendran sold 200,000 shares of the company’s stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $3.23, for a total transaction of $646,000.00. Following the completion of the transaction, the insider directly owned 1,006,439 shares in the company, valued at $3,250,797.97. This represents a 16.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.78% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Taysha Gene Therapies

Several institutional investors have recently modified their holdings of TSHA. China Universal Asset Management Co. Ltd. increased its holdings in shares of Taysha Gene Therapies by 27.7% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 52,527 shares of the company’s stock worth $121,000 after acquiring an additional 11,407 shares during the period. Marex Group plc acquired a new stake in shares of Taysha Gene Therapies in the second quarter valued at approximately $29,000. Tower Research Capital LLC TRC increased its stake in shares of Taysha Gene Therapies by 156.5% in the second quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock valued at $41,000 after purchasing an additional 10,742 shares during the period. E Fund Management Co. Ltd. bought a new stake in shares of Taysha Gene Therapies during the second quarter valued at approximately $31,000. Finally, Rafferty Asset Management LLC acquired a new position in shares of Taysha Gene Therapies during the second quarter worth approximately $274,000. Institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.